Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXEO Lexeo Therapeutics	$3.91 -7.8%	$3.36	$1.45 ▼ $19.50	$129.80M	0.52	530,292 shs	756,031 shs
PSTI Pluristem Therapeutics		$1.24	$0.95 ▼ $3.45	$32.35M	1.91	715,259 shs	2,128 shs
SGMO Sangamo Therapeutics	$0.46 -6.8%	$0.59	$0.30 ▼ $3.18	$106.67M	1.19	8.94 million shs	4.71 million shs
TARA Protara Therapeutics	$3.05 +2.3%	$3.41	$1.60 ▼ $10.48	$117.68M	1.34	776,277 shs	321,242 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXEO Lexeo Therapeutics	0.00%	-0.76%	+26.95%	+44.28%	-75.00%
PSTI Pluristem Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
SGMO Sangamo Therapeutics	0.00%	-6.82%	-7.48%	-47.21%	+8.62%
TARA Protara Therapeutics	0.00%	-2.87%	-3.79%	-33.70%	+30.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LXEO Lexeo Therapeutics	2.7914 of 5 stars	4.5	2.0	0.0	0.0	0.0	2.5	0.6
PSTI Pluristem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	1.3309 of 5 stars	3.3	2.0	0.0	0.0	0.0	0.8	0.6
TARA Protara Therapeutics	2.3442 of 5 stars	3.6	2.0	0.0	0.0	2.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	324.55% Upside
PSTI Pluristem Therapeutics	0.00	N/A	N/A	N/A
SGMO Sangamo Therapeutics	2.67	Moderate Buy	$4.50	883.61% Upside
TARA Protara Therapeutics	3.14	Buy	$20.50	572.13% Upside

Current Analyst Ratings Breakdown

Latest PSTI, LXEO, TARA, and SGMO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/22/2025	TARA Protara Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$21.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/14/2025	SGMO Sangamo Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $5.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
4/28/2025	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/16/2025	TARA Protara Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$12.00
4/8/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00
4/8/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/7/2025	SGMO Sangamo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/26/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LXEO Lexeo Therapeutics	$650K	199.71	N/A	N/A	$3.53 per share	1.11
PSTI Pluristem Therapeutics	$20K	0.00	N/A	N/A	$1.80 per share	0.00
SGMO Sangamo Therapeutics	$57.80M	1.85	N/A	N/A	$0.11 per share	4.16
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$4.77 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LXEO Lexeo Therapeutics	-$98.33M	-$3.30	N/A	N/A	N/A	N/A	-85.86%	-68.48%	8/11/2025 (Estimated)
PSTI Pluristem Therapeutics	-$49.87M	-$1.47	N/A	N/A	N/A	N/A	-100.63%	-55.46%	N/A
SGMO Sangamo Therapeutics	-$97.94M	-$0.39	N/A	N/A	N/A	-124.61%	-345.98%	-79.86%	8/5/2025 (Estimated)
TARA Protara Therapeutics	-$44.60M	-$1.72	N/A	N/A	N/A	N/A	-36.37%	-33.29%	8/5/2025 (Estimated)

Latest PSTI, LXEO, TARA, and SGMO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/12/2025	Q1 2025	SGMO Sangamo Therapeutics	-$0.11	-$0.14	-$0.03	-$0.14	$7.90 million	$6.44 million
5/8/2025	Q1 2025	TARA Protara Therapeutics	-$0.47	-$0.29	+$0.18	-$0.29	N/A	N/A
3/24/2025	Q4 2024	LXEO Lexeo Therapeutics	-$0.87	-$0.78	+$0.09	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
PSTI Pluristem Therapeutics	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LXEO Lexeo Therapeutics	0.01	3.42	3.42
PSTI Pluristem Therapeutics	0.57	8.22	8.22
SGMO Sangamo Therapeutics	N/A	0.76	0.76
TARA Protara Therapeutics	N/A	18.03	18.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LXEO Lexeo Therapeutics	60.67%
PSTI Pluristem Therapeutics	16.94%
SGMO Sangamo Therapeutics	56.93%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
LXEO Lexeo Therapeutics	5.30%
PSTI Pluristem Therapeutics	5.40%
SGMO Sangamo Therapeutics	4.10%
TARA Protara Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.44 million	Not Optionable
PSTI Pluristem Therapeutics	153	32.35 million	30.60 million	Optionable
SGMO Sangamo Therapeutics	480	233.17 million	223.61 million	Optionable
TARA Protara Therapeutics	30	38.58 million	35.34 million	Optionable

PSTI, LXEO, TARA, and SGMO Headlines

Recent News About These Companies

Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025

June 14, 2025 | seekingalpha.com

Two Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)

June 14, 2025 | marketbeat.com

Analysts Set Expectations for TARA FY2026 Earnings

June 10, 2025 | marketbeat.com

Chutes & Ladders—Protara gears up for next steps with commercial pro

June 7, 2025 | fiercebiotech.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DE

June 7, 2025 | marketbeat.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by Analysts

June 5, 2025 | marketbeat.com

The Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and more

June 4, 2025 | mmm-online.com

Protara Therapeutics names new Chief Commercial Officer

June 4, 2025 | investing.com

Millennium Management LLC Purchases 357,051 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

June 3, 2025 | marketbeat.com

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

June 2, 2025 | globenewswire.com

Toronto Dominion Bank Acquires New Stake in Protara Therapeutics, Inc. (NASDAQ:TARA)

May 30, 2025 | marketbeat.com

Protara Therapeutics (NASDAQ:TARA) Earns Buy Rating from Analysts at Jones Trading

May 24, 2025 | marketbeat.com

BNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA)

May 24, 2025 | marketbeat.com

Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation

May 23, 2025 | msn.com

Toronto Dominion Bank Takes Position in Protara Therapeutics, Inc. (NASDAQ:TARA)

May 23, 2025 | marketbeat.com

Richard Levy Spends US$64k On Protara Therapeutics Stock

May 22, 2025 | finance.yahoo.com

With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing

May 16, 2025 | finance.yahoo.com

Protara Therapeutics to Participate in Upcoming Investor Conferences

May 13, 2025 | globenewswire.com

Protara Therapeutics Reports Q1 2025 Financial Results

May 11, 2025 | tipranks.com

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

How Protara Therapeutics Reflects Shifts Among Nasdaq Companies by Market Cap

May 3, 2025 | kalkinemedia.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTI, LXEO, TARA, and SGMO Company Descriptions

Lexeo Therapeutics NASDAQ:LXEO

$3.91 -0.33 (-7.78%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.89 -0.02 (-0.51%)

As of 06/20/2025 06:43 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Pluristem Therapeutics NASDAQ:PSTI

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Sangamo Therapeutics NASDAQ:SGMO

$0.46 -0.03 (-6.84%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.47 +0.01 (+2.95%)

As of 06/20/2025 07:59 PM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Protara Therapeutics NASDAQ:TARA

$3.05 +0.07 (+2.35%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.06 +0.01 (+0.16%)

As of 06/20/2025 07:33 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time